In this issue of THE JOURNAL, Chaitman and colleagues1 report
the results of the Combination Assessment of Ranolazine In Stable Angina (CARISA)
trial, an important study evaluating ranolazine, a new antianginal drug. Ranolazine
is the first member of a new class of drugs believed to reduce angina by partially
inhibiting fatty acid oxidation, thereby increasing glucose oxidation and
generating more ATP (adenosine triphosphate) per molecule of oxygen consumed.2,3 In the Monotherapy Assessment of Ranolazine
In Stable Angina (MARISA) trial, an earlier placebo-controlled, double-blind
trial of the same drug, ranolazine reduced angina and objective evidence of
ischemia among patients who were taking no other antianginal medications.4 In CARISA, ranolazine reduced the frequency and severity
of angina and improved exercise duration in patients with stable angina receiving
other antianginal therapy, specifically those taking a standard dose of either
atenolol, amlopidine, or diltiazem. This well-designed, well-conducted clinical
trial in which patients were randomized to receive either 1 of 2 doses of
ranolazine or placebo showed that both doses of ranolazine were more effective
than placebo at reducing symptoms and improving exercise capacity when added
to conventional doses of atenolol, diltiazem, or amlopidine.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.